Literature DB >> 22379112

The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms.

Frank Weidemann1, Christian Rummey, Bart Bijnens, Stefan Störk, Ruta Jasaityte, Jan Dhooge, Aigul Baltabaeva, George Sutherland, Jörg B Schulz, Thomas Meier.   

Abstract

BACKGROUND: This cross-sectional study provides a practical approach for the clinical assessment of Friedreich ataxia (FA) cardiomyopathy (FA-CM). METHODS AND
RESULTS: A comprehensive cardiac assessment, including standard echocardiography, color Doppler myocardial imaging, cardiac magnetic resonance imaging, ECG, and exercise stress testing, was performed in 205 FA patients. To assess myocardial hypertrophy in FA-CM, the end-diastolic interventricular septal wall thickness (IVSTd) was found to be the best echocardiographic parameter compared with cardiac magnetic resonance imaging-determined left ventricular mass. With the use of this parameter, 4 groups of patients with FA-CM could be defined. Patients with normal values for IVSTd (31.7%) were classified as having no FA-CM. Patients with an IVSTd exceeding the predicted normal IVSTd were classified as having mild FA-CM (40%) if IVSTd exceeded the normal value by <18% or as having intermediate FA-CM (16.1%) if IVSTd exceeded the normal value by ≥18%. Patients with ejection fraction <50% were classified as having severe FA-CM (12.2%). In addition to increased myocardial mass, severe FA-CM was further characterized by dilatation of the left ventricle, reduced systolic strain rate of the posterior wall, and ECG abnormalities. Regional myocardial function correlated negatively with FA-CM groups. Younger patients had a tendency for more advanced FA-CM. Importantly, no clear correlation was found between FA-CM groups and neurological function.
CONCLUSIONS: We provide and describe a readily applicable clinical grouping of the cardiomyopathy associated with FA based on echocardiographic IVSTd and ejection fraction data. Because no distinct interrelations between FA-CM and neurological status could be determined, regular follow-up of potential cardiac involvement in FA patients is essential in clinical practice.

Entities:  

Mesh:

Year:  2012        PMID: 22379112     DOI: 10.1161/CIRCULATIONAHA.111.059477

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  29 in total

Review 1.  [Heart involvement in Friedreich's ataxia].

Authors:  F Weidemann; F Scholz; C Florescu; D Liu; K Hu; S Herrmann; G Ertl; S Störk
Journal:  Herz       Date:  2014-05-23       Impact factor: 1.443

Review 2.  MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis.

Authors:  Ying-Han R Hsu; Haran Yogasundaram; Nirmal Parajuli; Lucas Valtuille; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2016-01       Impact factor: 4.214

3.  The dynamin-related protein 1 is decreased and the mitochondrial network is altered in Friedreich's ataxia cardiomyopathy.

Authors:  Bojjibabu Chidipi; Mariana Burgos Angulo; Syed Islamuddin Shah; Michelle Rieser; Ganim Ullah; Thomas V McDonald; Sami F Noujaim
Journal:  Int J Biochem Cell Biol       Date:  2021-12-16       Impact factor: 5.085

Review 4.  Pharmacological treatments for Friedreich ataxia.

Authors:  Mary Kearney; Richard W Orrell; Michael Fahey; Ruth Brassington; Massimo Pandolfo
Journal:  Cochrane Database Syst Rev       Date:  2016-08-30

Review 5.  Iron-sulfur cluster biogenesis in mammalian cells: New insights into the molecular mechanisms of cluster delivery.

Authors:  Nunziata Maio; Tracey A Rouault
Journal:  Biochim Biophys Acta       Date:  2014-09-19

6.  Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database.

Authors:  Günther Metz; Nicholas Coppard; Jonathon M Cooper; Martin B Delatycki; Alexandra Dürr; Nicholas A Di Prospero; Paola Giunti; David R Lynch; J B Schulz; Christian Rummey; Thomas Meier
Journal:  Brain       Date:  2013-01       Impact factor: 13.501

7.  Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia.

Authors:  Morgane Perdomini; Brahim Belbellaa; Laurent Monassier; Laurence Reutenauer; Nadia Messaddeq; Nathalie Cartier; Ronald G Crystal; Patrick Aubourg; Hélène Puccio
Journal:  Nat Med       Date:  2014-04-06       Impact factor: 53.440

Review 8.  Cardiac Involvement in Movement Disorders.

Authors:  Malco Rossi; Nestor Wainsztein; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2021-04-07

Review 9.  Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain.

Authors:  Hidekazu Tanaka
Journal:  J Echocardiogr       Date:  2021-01-18

Review 10.  Diagnosis and management of hypertrophic cardiomyopathy.

Authors:  Antonis Pantazis; Annina S Vischer; Maria Carrillo Perez-Tome; Silvia Castelletti
Journal:  Echo Res Pract       Date:  2015-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.